MA50502A - Adénovirus et utilisations associées - Google Patents
Adénovirus et utilisations associéesInfo
- Publication number
- MA50502A MA50502A MA050502A MA50502A MA50502A MA 50502 A MA50502 A MA 50502A MA 050502 A MA050502 A MA 050502A MA 50502 A MA50502 A MA 50502A MA 50502 A MA50502 A MA 50502A
- Authority
- MA
- Morocco
- Prior art keywords
- adenovirus
- related uses
- Prior art date
Links
- 241000701161 unidentified adenovirus Species 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A61K39/135—Foot- and mouth-disease virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10371—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17199348 | 2017-10-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA50502A true MA50502A (fr) | 2020-09-09 |
Family
ID=60413037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA050502A MA50502A (fr) | 2017-10-31 | 2018-10-30 | Adénovirus et utilisations associées |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11236361B2 (fr) |
| EP (1) | EP3704138A1 (fr) |
| JP (1) | JP7366014B2 (fr) |
| KR (1) | KR20200074987A (fr) |
| CN (1) | CN111372943B (fr) |
| AU (1) | AU2018357912B2 (fr) |
| CA (1) | CA3078771A1 (fr) |
| EA (1) | EA202091004A1 (fr) |
| IL (1) | IL274217A (fr) |
| MA (1) | MA50502A (fr) |
| MX (1) | MX2020004488A (fr) |
| SG (1) | SG11202003290RA (fr) |
| WO (1) | WO2019086456A1 (fr) |
| ZA (1) | ZA202002184B (fr) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201507393TA (en) | 2013-03-14 | 2015-10-29 | Salk Inst For Biological Studi | Oncolytic adenovirus compositions |
| ES2899913T3 (es) | 2014-09-24 | 2022-03-15 | Salk Inst For Biological Studi | Virus tumorales oncolíticos y métodos de uso |
| EP3390645B1 (fr) | 2016-02-23 | 2022-09-14 | Salk Institute for Biological Studies | Expression d'un gène exogene d'un adenovirus therapeutique avec impact minimaire sur la cinetique virale |
| WO2017147265A1 (fr) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | Dosage à haut débit pour mesurer la cinétique de réplication d'un adénovirus |
| AU2017375633C1 (en) | 2016-12-12 | 2023-04-27 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
| BR112020019942A2 (pt) | 2018-04-09 | 2021-01-26 | Salk Institute For Biological Studies | composições de adenovírus oncolítico com propriedades de replicação aprimoradas |
| NL2023464B1 (en) | 2019-07-09 | 2021-02-02 | Academisch Ziekenhuis Leiden | Oncolytic Non-human adenoviruses and uses thereof |
| CA3156471A1 (fr) * | 2019-10-03 | 2021-04-08 | Janssen Vaccines & Prevention B.V. | Vecteurs d'adenovirus et leurs utilisations |
| TW202204380A (zh) | 2020-01-31 | 2022-02-01 | 美商詹森藥物公司 | 用於預防及治療冠狀病毒感染之組合物及方法-sars-cov-2疫苗 |
| KR20230009445A (ko) | 2020-05-11 | 2023-01-17 | 얀센 파마슈티칼즈, 인코포레이티드 | 안정화된 코로나바이러스 스파이크 단백질 융합 단백질 |
| EP4171627A1 (fr) | 2020-06-29 | 2023-05-03 | Janssen Vaccines & Prevention B.V. | Association de vaccin contre une infection par le virus respiratoire syncytial |
| TWI901715B (zh) * | 2020-07-01 | 2025-10-21 | 義大利商萊伊錫拉有限責任公司 | 大猩猩腺病毒核酸及胺基酸序列,包含彼之載體,及其用途 |
| BR112022026974A2 (pt) | 2020-07-06 | 2023-01-24 | Janssen Pharmaceuticals Inc | Proteínas de fusão estabilizadas de proteínas de pico de coronavírus |
| US20240228548A9 (en) | 2021-02-19 | 2024-07-11 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion rsv fb antigens |
| WO2022175479A1 (fr) | 2021-02-19 | 2022-08-25 | Janssen Vaccines & Prevention B.V. | Associations de vaccins contre les infections par les souches a et b du virus respiratoire syncytial |
| KR20230150269A (ko) | 2021-02-23 | 2023-10-30 | 얀센 백신스 앤드 프리벤션 비.브이. | Hiv 외피 단백질 돌연변이를 안정화시키는 삼량체 |
| US20250277234A1 (en) * | 2021-03-29 | 2025-09-04 | Genematrix, Inc. | Recombinant chimeric adenoviral vector substituted by knob gene of chimpanzee adenovirus serotype 6, and application thereof |
| AU2022249741A1 (en) | 2021-04-01 | 2023-09-21 | Msd International Business Gmbh | Stabilized pre-fusion piv3 f proteins |
| WO2023020939A1 (fr) | 2021-08-17 | 2023-02-23 | Janssen Pharmaceuticals, Inc. | Vaccins contre le sars-cov-2 |
| WO2023026182A1 (fr) | 2021-08-24 | 2023-03-02 | Janssen Pharmaceuticals, Inc. | Vaccins anti-sars-cov-2 |
| WO2023047349A1 (fr) | 2021-09-24 | 2023-03-30 | Janssen Pharmaceuticals, Inc. | Protéines de fusion protéines de spicule de coronavirus stabilisées |
| WO2023047348A1 (fr) | 2021-09-24 | 2023-03-30 | Janssen Pharmaceuticals, Inc. | Protéines de fusion de protéine de spicule de coronavirus stabilisées |
| WO2023111725A1 (fr) | 2021-12-14 | 2023-06-22 | Janssen Pharmaceuticals, Inc. | Vaccins anti-sars-cov-2 |
| EP4448802A1 (fr) | 2021-12-16 | 2024-10-23 | Janssen Vaccines & Prevention B.V. | Protéines de fusion hmpv pré-hybrides stabilisées |
| WO2023156505A1 (fr) | 2022-02-17 | 2023-08-24 | Janssen Vaccines & Prevention B.V. | Trimère stabilisant les mutations de protéines d'enveloppe du vih r304v, n302m et t320l |
| WO2024061759A1 (fr) | 2022-09-23 | 2024-03-28 | Janssen Vaccines & Prevention B.V. | Protéines s de coronavirus stabilisées |
| EP4590690A1 (fr) | 2022-09-23 | 2025-07-30 | Janssen Vaccines & Prevention B.V. | Protéines f du piv1 humain en pré-fusion |
| WO2024074584A1 (fr) | 2022-10-06 | 2024-04-11 | Janssen Vaccines & Prevention B.V. | Protéines f du piv3 sous forme pré-fusion stabilisées |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2705686B1 (fr) | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
| US5851806A (en) | 1994-06-10 | 1998-12-22 | Genvec, Inc. | Complementary adenoviral systems and cell lines |
| EP0784690B1 (fr) | 1994-06-10 | 2006-08-16 | Genvec, Inc. | Systemes de vecteurs adenoviraux et lignees cellulaires complementaires |
| US5965541A (en) | 1995-11-28 | 1999-10-12 | Genvec, Inc. | Vectors and methods for gene transfer to cells |
| US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
| US5559099A (en) | 1994-09-08 | 1996-09-24 | Genvec, Inc. | Penton base protein and methods of using same |
| DE69633565T3 (de) | 1995-06-15 | 2013-01-17 | Crucell Holland B.V. | Verpackungssysteme für humane, menschliche adenoviren, zur verwendung in die gentherapie |
| US5837511A (en) | 1995-10-02 | 1998-11-17 | Cornell Research Foundation, Inc. | Non-group C adenoviral vectors |
| US5891690A (en) | 1996-04-26 | 1999-04-06 | Massie; Bernard | Adenovirus E1-complementing cell lines |
| CA2283253A1 (fr) | 1997-03-04 | 1998-09-11 | Baxter International Inc. | Lignees cellulaires de complementation de la region e1 d'un adenovirus |
| US6020191A (en) | 1997-04-14 | 2000-02-01 | Genzyme Corporation | Adenoviral vectors capable of facilitating increased persistence of transgene expression |
| US5981225A (en) | 1998-04-16 | 1999-11-09 | Baylor College Of Medicine | Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same |
| US6113913A (en) | 1998-06-26 | 2000-09-05 | Genvec, Inc. | Recombinant adenovirus |
| WO2003104467A1 (fr) | 2002-04-25 | 2003-12-18 | Crucell Holland B.V. | Moyens et procede de production de vecteurs d'adenovirus |
| JP2003530307A (ja) | 1999-07-06 | 2003-10-14 | メルク・アンド・カンパニー・インコーポレーテッド | gag遺伝子保有アデノウイルスHIVワクチン |
| DE19955558C2 (de) | 1999-11-18 | 2003-03-20 | Stefan Kochanek | Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren |
| JP2004508064A (ja) | 2000-09-15 | 2004-03-18 | メルク エンド カムパニー インコーポレーテッド | コドン最適化hiv1−gag、pol、nefおよび修飾体を発現する増強された第1世代アデノウイルスワクチン |
| AU2002308713B2 (en) | 2001-06-22 | 2008-05-15 | The Trustees Of The University Of Pennsylvania | Methods of inducing a cytotoxic immune response and recombinant simian adenovirus compositions useful therein |
| US8232255B2 (en) | 2002-10-23 | 2012-07-31 | Glaxosmithkline Biologicals S.A. | Methods for vaccinating against malaria |
| JP4814800B2 (ja) * | 2004-01-23 | 2011-11-16 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | チンパンジーアデノウイルスワクチン担体 |
| US7741099B2 (en) | 2004-10-13 | 2010-06-22 | Beth Israel Deaconess Medical Center Inc. | Adenoviral vectors and uses thereof |
| CN101072879B (zh) * | 2004-10-13 | 2011-05-11 | 克鲁塞尔荷兰公司 | 改良的腺病毒载体及其应用 |
| WO2007104792A2 (fr) | 2006-03-16 | 2007-09-20 | Crucell Holland B.V. | Adénovirus recombinés basés sur les sérotypes 26 et 48 et utilisation de ceux-ci |
| KR101662574B1 (ko) * | 2007-11-28 | 2016-10-05 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 유인원 e 아데노바이러스 sadv-39, -25.2, -26, -30, -37, 및 -38 |
| EA019928B1 (ru) | 2008-11-03 | 2014-07-30 | Круселл Холланд Б.В. | Способ получения аденовирусных векторов |
| HUE039908T2 (hu) * | 2009-02-02 | 2019-02-28 | Glaxosmithkline Biologicals Sa | Majom adenovírusból származó nukleinsav- és aminosav-szekvenciák, azt tartalmazó vektorok és alkalmazásuk |
| PL2536829T3 (pl) | 2010-02-15 | 2016-09-30 | Sposób wytwarzania wektorów adenowirusowych Ad26 | |
| WO2011130627A2 (fr) | 2010-04-16 | 2011-10-20 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Vaccins contre des filovirus basés sur des vecteurs adénoviraux de chimpanzé |
| WO2013016591A1 (fr) | 2011-07-26 | 2013-01-31 | Zuvachem, Inc. | Isoprène synthases à efficacité élevée produites par l'ingénierie protéique |
| WO2013052859A2 (fr) | 2011-10-05 | 2013-04-11 | Genvec, Inc. | Vaccin contre le virus respiratoire syncytial à base d'un vecteur adénoviral |
| AU2013262626B2 (en) * | 2012-05-18 | 2018-11-29 | The Trustees Of The University Of Pennsylvania | Subfamily E simian adenoviruses A1302, A1320, A1331 and A1337 and uses thereof |
-
2018
- 2018-10-30 MX MX2020004488A patent/MX2020004488A/es unknown
- 2018-10-30 JP JP2020524185A patent/JP7366014B2/ja active Active
- 2018-10-30 AU AU2018357912A patent/AU2018357912B2/en not_active Ceased
- 2018-10-30 US US16/760,518 patent/US11236361B2/en not_active Expired - Fee Related
- 2018-10-30 CN CN201880071256.8A patent/CN111372943B/zh active Active
- 2018-10-30 EA EA202091004A patent/EA202091004A1/ru unknown
- 2018-10-30 EP EP18796013.3A patent/EP3704138A1/fr not_active Withdrawn
- 2018-10-30 CA CA3078771A patent/CA3078771A1/fr active Pending
- 2018-10-30 WO PCT/EP2018/079713 patent/WO2019086456A1/fr not_active Ceased
- 2018-10-30 MA MA050502A patent/MA50502A/fr unknown
- 2018-10-30 KR KR1020207014975A patent/KR20200074987A/ko not_active Ceased
- 2018-10-30 SG SG11202003290RA patent/SG11202003290RA/en unknown
-
2020
- 2020-04-26 IL IL274217A patent/IL274217A/en unknown
- 2020-05-04 ZA ZA2020/02184A patent/ZA202002184B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL274217A (en) | 2020-06-30 |
| CA3078771A1 (fr) | 2019-05-09 |
| CN111372943B (zh) | 2023-12-05 |
| US11236361B2 (en) | 2022-02-01 |
| JP2021500908A (ja) | 2021-01-14 |
| CN111372943A (zh) | 2020-07-03 |
| EA202091004A1 (ru) | 2020-08-10 |
| KR20200074987A (ko) | 2020-06-25 |
| ZA202002184B (en) | 2022-06-29 |
| AU2018357912B2 (en) | 2023-11-09 |
| MX2020004488A (es) | 2020-08-13 |
| WO2019086456A1 (fr) | 2019-05-09 |
| US20210198690A1 (en) | 2021-07-01 |
| SG11202003290RA (en) | 2020-05-28 |
| JP7366014B2 (ja) | 2023-10-20 |
| WO2019086456A8 (fr) | 2019-07-18 |
| AU2018357912A1 (en) | 2020-04-23 |
| EP3704138A1 (fr) | 2020-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL293377A (en) | Hsd17b13 variants and uses thereof | |
| HRP20260186T1 (hr) | Inkretinski analozi i njihova upotreba | |
| MA50618A (fr) | Polyrhérapies et leurs utilisations | |
| EP3334706A4 (fr) | Pillararènes et utilisations de ceux-ci | |
| PT3667980T (pt) | Indicar e receber localização de recurso | |
| DK3610005T3 (da) | Peptidligase og anvendelse deraf | |
| DK3668512T3 (da) | Pyruvatkinasemodulatorer og anvendelse deraf | |
| EP3749315A4 (fr) | Raltitrexed alpha-polyglutamaté et utilisations associées | |
| EP3749318A4 (fr) | Raltitrexed gamma-polyglutamaté et utilisations associées | |
| MA46700A (fr) | Variants polypeptidiques et ses utilisations | |
| EP3790861A4 (fr) | Compositions sénolytiques et utilisations associées | |
| EP3413816A4 (fr) | Compositions hydratantes et utilisations associées | |
| PL3265448T3 (pl) | Proleki riluzolu i ich zastosowanie | |
| EP3652235A4 (fr) | Polymère électrochromique et synthèse et utilisations associées | |
| MA44262A (fr) | Bioconjugués et utilisations de ceux-ci | |
| EP3583219A4 (fr) | Compositions probiotiques et utilisations correspondantes | |
| PL3319612T3 (pl) | Oksysterole i sposoby ich stosowania | |
| EP3356558A4 (fr) | Biomarqueurs pathogènes et utilisations associées | |
| DK3128005T3 (da) | Sirp-alfa-variantkonstruktioner og anvendelser deraf | |
| EP3570829A4 (fr) | Ligands photoréactifs et utilisations | |
| EP3511407A4 (fr) | Christensenella intestinihominis et son application | |
| DK3672948T3 (da) | Pyridinamin-pyridon- og pyrimidinamin-pyridonforbindelser | |
| EP3517118A4 (fr) | Activateur de sperme et utilisations associées | |
| EP3347021A4 (fr) | Cyano-thiénotriazoloazépines et leurs utilisations | |
| EP3544606A4 (fr) | Agents psychotropes et leurs utilisations |